WEST CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Today Zelos Therapeutics announced that it released data in two presentations at the 29th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) that represent strong proof of concept for cyclic PTH (1-31) (Ostabolin-C™) as an osteoporosis therapeutic. The data were from a 12-month Phase 2 randomized, placebo-controlled, dose-ranging trial of subcutaneous Ostabolin-C in post-menopausal women with diagnosed osteoporosis, and a Phase 1 healthy volunteer study in post-menopausal women of an inhaled formulation of Ostabolin-C developed with Nektar Therapeutics. Ostabolin-C, a proprietary cyclic parathyroid hormone (PTH) analogue, is in late stage clinical development for the treatment of osteoporosis.
